Search Results - "Masakatsu Nishikawa"

Efficacy and Safety of Adjusted-Dose Prasugrel Compared With Clopidogrel in Japanese Patients With Acute Coronary Syndrome: The PRASFIT-ACS Study by Saito, Shigeru, Isshiki, Takaaki, Kimura, Takeshi, Ogawa, Hisao, Yokoi, Hiroyoshi, Nanto, Shinsuke, Takayama, Morimasa, Kitagawa, Kazuo, Nishikawa, Masakatsu, Miyazaki, Shunichi, Nakamura, Masato

“…Background: Prasugrel is an antiplatelet agent that shows more prompt, potent, and consistent platelet inhibition than clopidogrel. The objective of this study…”
Get full text

Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-I Randomized Controlled Trial by Kitazono, Takanari, Toyoda, Kazunori, Kitagawa, Kazuo, Nagao, Takehiko, Yamagami, Hiroshi, Uchiyama, Shinichiro, Tanahashi, Norio, Matsumoto, Masayasu, Minematsu, Kazuo, Nagata, Izumi, Nishikawa, Masakatsu, Nanto, Shinsuke, Ikeda, Yasuo, Shirai, Toshiaki, Abe, Kenji, Ogawa, Akira, Group, PRASTRO-I Study

“…Aims: The efficacy of antiplatelet therapy may vary among different disease subtypes. Prasugrel is generally a more potent, consistent, and fast-acting…”
Get full text

Echocardiographic Assessment of Cardiac Structural and Functional Abnormalities in Patients With End-Stage Renal Disease Receiving Chronic Hemodialysis by Matsuo, Hiroshi, Dohi, Kaoru, Machida, Hirofumi, Takeuchi, Hideyuki, Aoki, Toshikazu, Nishimura, Hiroyuki, Yasutomi, Masashi, Senga, Michiharu, Ichikawa, Takehiko, Kakuta, Kentaro, Mizutani, Yasuhide, Tanoue, Akiko, Isaka, Naoki, Oosugi, Kazuki, Koyabu, Sukenari, Sakurai, Masato, Fukui, Yoshihisa, Kakimoto, Hitoshi, Sugimoto, Tadafumi, Ohnishi, Takahiro, Murata, Tomohiro, Ishikawa, Eiji, Okamoto, Ryuji, Yamada, Tomomi, Ogura, Toru, Nishimura, Yuki, Tanigawa, Takashi, Nomura, Shinsuke, Nishikawa, Masakatsu, Ito, Masaaki

“…Background:The aim of this study was to assess the echocardiographic characteristics of chronic hemodialysis (HD) patients with end-stage renal disease (ESRD)…”
Get full text

Prasugrel, a Third-Generation P2Y12 Receptor Antagonist, in Patients With Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention: Phase III, Randomized, Double-Blind Study by Isshiki, Takaaki, Kimura, Takeshi, Ogawa, Hisao, Yokoi, Hiroyoshi, Nanto, Shinsuke, Takayama, Morimasa, Kitagawa, Kazuo, Nishikawa, Masakatsu, Miyazaki, Shunichi, Ikeda, Yasuo, Nakamura, Masato, Saito, Shigeru, on behalf of the PRASFIT-Elective Investigators

“…Background:Prasugrel is being developed in Japan as an antiplatelet therapy for use during percutaneous coronary intervention (PCI). Up to 70% of Japanese…”
Get full text

DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study by Miyazaki, Kana, Asano, Naoko, Yamada, Tomomi, Miyawaki, Kohta, Sakai, Rika, Igarashi, Tadahiko, Nishikori, Momoko, Ohata, Kinya, Sunami, Kazutaka, Yoshida, Isao, Yamamoto, Go, Takahashi, Naoki, Okamoto, Masataka, Yano, Hiroki, Nishimura, Yuki, Tamaru, Satoshi, Nishikawa, Masakatsu, Izutsu, Koji, Kinoshita, Tomohiro, Suzumiya, Junji, Ohshima, Koichi, Kato, Koji, Katayama, Naoyuki, Yamaguchi, Motoko

“…CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is characterized by poor prognosis and a high frequency of central nervous system relapse after…”
Get full text

Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation by Nishikawa, Masakatsu, Takeda, Yoshihiro, Isomura, Naoei, Tanigawa, Takashi, Nanasato, Mamoru, Tsukahara, Kengo, Kimura, Kazuo, Takayama, Tadateru, Hirayama, Atsushi, Kato, Masafumi, Nishikawa, Hideo, Nishimura, Yuki, Isshiki, Takaaki, Yokoi, Hiroyoshi, group, for the j-CHIPS

“…Aim: Although high on-treatment platelet reactivity (HTPR) with dual antiplatelet therapy (DAPT) correlates with long-term adverse outcomes in patients…”
Get full text

Incidence of stroke, systemic embolism and bleeding events in patients without anticoagulation based on real-world data in Japan: a retrospective cohort study by Tanizawa, Kimihiko, Nishimura, Yuki, Sera, Shoji, Yaguchi, Daichi, Okada, Akira, Nishikawa, Masakatsu, Tamaru, Satoshi, Nagai, Naomi

“…ObjectivesTo examine the incidence of stroke or systemic embolic events (SSEs) and bleeding events in untreated patients with non-valvular atrial fibrillation…”
Get full text

Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study) by Nakamura, Mashio, Nishikawa, Masakatsu, Komuro, Issei, Kitajima, Isao, Uetsuka, Yoshio, Yamagami, Takuji, Minamiguchi, Hiroki, Yoshimatsu, Rika, Tanabe, Kosuke, Matsuoka, Nobushige, Kanmuri, Kazuhiro, Ogawa, Hisao

“…Background:Anticoagulation is recommended as standard of care for venous thromboembolism (VTE) (pulmonary embolism [PE]/deep vein thrombosis [DVT]), for which…”
Get full text

Effect of Combination Therapy of Ezetimibe and Rosuvastatin on Regression of Coronary Atherosclerosis in Patients With Coronary Artery Disease by Masuda, Jun, Tanigawa, Takashi, Yamada, Tomomi, Nishimura, Yuki, Sasou, Takashi, Nakata, Tomoyuki, Sawai, Toshiki, Fujimoto, Naoki, Dohi, Kaoru, Miyahara, Masatoshi, Nishikawa, Masakatsu, Nakamura, Mashio, Ito, Masaaki

“…Ezetimibe has been reported to provide significant incremental reduction in low-density-lipoprotein cholesterol (LDL-C) when added to a statin; however, its…”
Get full text

Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study by Ogawa, Hisao, MD, FJCC, Isshiki, Takaaki, MD, FJCC, Kimura, Takeshi, MD, FJCC, Yokoi, Hiroyoshi, MD, Nanto, Shinsuke, MD, FJCC, Takayama, Morimasa, MD, FJCC, Kitagawa, Kazuo, MD, Nishikawa, Masakatsu, MD, Miyazaki, Shunichi, MD, FJCC, Ikeda, Yasuo, MD, Nakamura, Masato, MD, FJCC, Tanaka, Yuko, MS, Saito, Shigeru, MD, FJCC

“…Abstract Background We examined the effects of cytochrome P450 2C19 (CYP2C19) polymorphisms on the efficacy and safety of prasugrel and clopidogrel in a post…”
Get full text

Impact of Arterial Access Route on Bleeding Complications in Japanese Patients Undergoing Percutaneous Coronary Intervention　– Insight From the PRASFIT Trial by Saito, Shigeru, Isshiki, Takaaki, Kimura, Takeshi, Ogawa, Hisao, Yokoi, Hiroyoshi, Nishikawa, Masakatsu, Miyazaki, Shunichi, Tanaka, Yuko, Nakamura, Masato, on behalf of the PRASFIT-ACS and PRASFIT-Elective Investigators

“…Background:Few large-scale studies have examined the relationship between bleeding events not related to coronary artery bypass grafting (CABG), and the…”
Get full text

Exploratory rivaroxaban trial for isolated calf deep vein thrombosis with a risk factor of thrombosis extension: an open-label, multicenter, randomized controlled trial by Ogihara, Yoshito, Yamada, Norikazu, Izumi, Daisuke, Sato, Yuichi, Sato, Toru, Nakaya, Hitoshi, Mori, Tatsuya, Ota, Satoshi, Makino, Midori, Ogura, Toru, Tamaru, Satoshi, Nishimura, Yuki, Tanigawa, Takashi, Kasai, Atsunobu, Nishikawa, Masakatsu, Dohi, Kaoru

“…Limited evidence exists regarding the incidence of recurrent venous thromboembolism (VTE) in patients diagnosed with isolated distal deep vein thrombosis (DVT)…”
Get full text

Developmental Changes in Neonatal and Infant Skin Structures During the First 6 Months: In Vivo Observation by Miyauchi, Yuki, Shimaoka, Yayoi, Fujimura, Tsutomu, Koike, Yumi, Yatabe, Michio, Nishikawa, Masakatsu, Hayashi, Masaru, Sugata, Keiichi, Moriwaki, Shigeru, Hatamochi, Atsushi

“…Background/Objectives Developmental changes of structures in neonatal and infant skin have not been well characterized. The purpose of this study was to…”
Get full text

Relationship Between CYP2C19 Loss-of-Function Polymorphism and Platelet Reactivities With Clopidogrel Treatment in Japanese Patients Undergoing Coronary Stent Implantation by Nakata, Tomoyuki, Miyahara, Masatoshi, Nakatani, Kaname, Wada, Hideo, Tanigawa, Takashi, Komada, Fumihiko, Hoshino, Kozo, Aoki, Toshikazu, Nishimura, Yuki, Tamaru, Satoshi, Ito, Masaaki, Nishikawa, Masakatsu, group, for the McLORDD

“…Background: CYP2C19 loss-of-function genotype (*2 and/or *3 alleles) is related to low responsiveness to clopidogrel, which is a risk factor for ischemic…”
Get full text

Novel acoustic evaluation system for scratching behavior in itching dermatitis: Rapid and accurate analysis for nocturnal scratching of atopic dermatitis patients by Noro, Yuichi, Omoto, Youichi, Umeda, Koji, Tanaka, Futa, Shiratsuka, Yousuke, Yamada, Tomomi, Isoda, Kenichi, Matsubara, Kimiko, Yamanaka, Keiichi, Gabazza, Esteban C., Nishikawa, Masakatsu, Mizutani, Hitoshi

“…Quantitative analysis of itching in patients with itching dermatitis including atopic dermatitis (AD) is indispensable for the evaluation of disease activity…”
Get full text

Inhibitory Phosphorylation Site for Rho-associated Kinase on Smooth Muscle Myosin Phosphatase by Feng, J, Ito, M, Ichikawa, K, Isaka, N, Nishikawa, M, Hartshorne, D J, Nakano, T

“…It is clear from several studies that myosin phosphatase (MP) can be inhibited via a pathway that involves RhoA. However, the mechanism of inhibition is not…”
Get full text

Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients by Nagatsuka, Kazuyuki, Miyata, Shigeki, Kada, Akiko, Kawamura, Atsushi, Nakagawara, Jyoji, Furui, Eisuke, Takiuchi, Shin, Taomoto, Katsushi, Kario, Kazuomi, Uchiyama, Shinichiro, Saito, Kozue, Nagao, Takehiko, Kitagawa, Kazuo, Hosomi, Naohisa, Tanaka, Keiji, Kaikita, Koichi, Katayama, Yasuo, Abumiya, Takeo, Nakane, Hiroshi, Wada, Hideo, Hattori, Akira, Kimura, Kazumi, Isshiki, Takaaki, Nishikawa, Masakatsu, Yamawaki, Takemori, Yonemoto, Naohiro, Okada, Hiromi, Ogawa, Hisao, Minematsu, Kazuo, Miyata, Toshiyuki

“…Several studies have indicated that approximately 25 % of patients treated with aspirin exhibit high on-treatment platelet reactivity (HTPR), which is…”
Get more information

HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan by KITANO, Shigehisa, KAGEYAMA, Shinichi, NISHIKAWA, Masakatsu, SUNAMOTO, Junzo, AKIYOSHI, Kazunari, KANEMATSU, Takashi, SCOTT, Andrew M, MURPHY, Roger, HOFFMAN, Eric W, OLD, Lloyd J, SHIKU, Hiroshi, NAGATA, Yasuhiro, MIYAHARA, Yoshihiro, HIASA, Atsunori, NAOTA, Hiroaki, OKUMURA, Satoshi, IMAI, Hiroshi, SHIRAISHI, Taizo, MASUYA, Masahiro

“…Purpose: We developed a complex of tumor antigen protein with a novel nanoparticle antigen delivery system of cholesteryl pullulan (CHP). To target HER2…”
Get full text

Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy by Miyakawa, Yoshitaka, Katsutani, Shinya, Yano, Takahiro, Nomura, Shosaku, Nishiwaki, Kaichi, Tomiyama, Yoshiaki, Higashihara, Masaaki, Shirasugi, Yukari, Nishikawa, Masakatsu, Ozaki, Katsutoshi, Abe, Takayuki, Kikuchi, Kayoko, Kanakura, Yuzuru, Fujimura, Kingo, Ikeda, Yasuo, Okamoto, Shinichiro

“…Primary immune thrombocytopenia (ITP) is an autoimmune disease mediated by the production of auto-antibody against platelets. Rituximab, an anti-CD20 antibody,…”
Get full text

Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats by Zhang, Erquan, Maruyama, Junko, Yokochi, Ayumu, Mitani, Yoshihide, Sawada, Hirofumi, Nishikawa, Masakatsu, Ma, Ning, Maruyama, Kazuo

“…Purpose The purpose of the present study was to determine if sarpogrelate hydrochloride (SPG), a serotonin 5HT2A receptor antagonist, prevented the development…”
Get full text